Skye Bioscience, Inc.

Skye Bioscience, Inc. is a U.S.-based clinical-stage biotechnology company focused on developing GPCR-modulating therapies for obesity, overweight, and related conditions. Its lead program, nimacimab, is a subcutaneous injectable antibody targeting the CB1 receptor, and the company operates through a small corporate structure with subsidiaries in the United States, Australia, and Canada.

3.30

3.30

— Skye Bioscience, Inc.
%
Lead clinical program100% Development of nimacimab, a CB1-targeting antibody for obesity and related metabolic conditions.
Discovery and preclinical pipeline0% Early-stage research on additional GPCR-modulating molecules and related assets.
Clinical development services0% Use of CROs, investigative sites, and consultants to run trials and support regulatory advancement.
Manufacturing and CMC development0% Third-party manufacturing and process development for nimacimab and future biologics.

Skye Bioscience does not yet commercialize products, so its near-term counterparties are primarily clinical trial...

  • Clinical research partnersprimary

    CROs, investigators, and trial sites that execute nimacimab studies and generate clinical data.

  • Manufacturing partnersprimary

    Third-party biologics manufacturers and consultants that support drug substance and drug product supply.

  • Future prescribers and care providerssecondary

    Physicians and obesity-treatment providers who would prescribe nimacimab if approved.

  • Potential collaboration partnerssecondary

    Pharmaceutical or biotech partners that may provide funding, development support, or commercialization reach.

Skye Bioscience is headquartered in San Diego, California and also maintains administrative office space in San...

  • •Headquartered in San Diego, California
  • •Administrative office space in San Francisco, California
  • •Subsidiaries in the United States, Australia, and Canada
  • •Clinical and manufacturing work is outsourced across partner locations
  • •No disclosed revenue by country because the company has no revenue

Skye Bioscience’s strategy centers on advancing nimacimab through clinical development and building evidence for its...

01
Advance nimacimab through clinical trialsshort-term

Clinical proof-of-concept is the main value driver for a pre-commercial biotech.

02
Secure manufacturing and development partnersshort-term

The company depends on external providers for clinical supply and trial execution.

03
Expand the GPCR-based pipelinemedium-term

A broader pipeline can diversify scientific risk beyond a single lead asset.

04
Prepare for future commercialization or partneringmedium-term

Approval would require sales, distribution, and market access capabilities.

Skye Bioscience faces the typical risks of a clinical-stage biotech: uncertain trial outcomes, dependence on external...

critical

Clinical development failure for nimacimab

The company’s value is concentrated in a single lead program and clinical outcomes are uncertain.

Scope
Lead obesity program
Materiality
high
high

Dependence on third-party manufacturers and CROs

Skye lacks internal commercial and manufacturing infrastructure, creating execution and supply risk.

Scope
Clinical supply and trial operations
Materiality
high
high

Need for additional financing

Development-stage biotech programs consume cash before any product revenue is generated.

Scope
Operating runway and trial funding
Materiality
high
high

Competition from larger biopharma companies

Competitors may have more resources, broader pipelines, and faster development capabilities.

Scope
Obesity and metabolic disease
Materiality
medium
medium

Intellectual property protection

The company’s ability to defend its proprietary molecules and methods affects long-term value.

Scope
Nimacimab and GPCR platform
Materiality
medium
Accrued research and development expenses
Can shift expense recognition between quarters
Fair value of acquired assets
Can influence intangible asset balances and future impairment risk
Legal contingencies
May create one-time gains, losses, or reserve changes
Stock-based compensation
Affects reported G&A and R&D costs

Spyre Therapeutics, Inc.

SYRE · Pharmaceutical Preparations

iBio, Inc.

IBIO · Pharmaceutical Preparations

Corbus Pharmaceuticals Holdings, Inc.

CRBP · Pharmaceutical Preparations

Viking Therapeutics, Inc.

VKTX · Pharmaceutical Preparations

Zymeworks Inc.

ZYME · Pharmaceutical Preparations

Cosmos Health Inc.

COSM · Wholesale-Drugs, Proprietaries & Druggists' Sundries

: 29/04/2026